New drug duo aims to slow advanced breast cancer
NCT ID NCT07195227
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests two drugs, camizestrant and ribociclib, together in people with advanced hormone receptor-positive (HR+) breast cancer. The goal is to see if the combination can delay cancer growth better than current treatments. About 150 adults who have already received hormone therapy for at least 5 years will take part. The main focus is on how long the cancer stays under control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
camizestrant and ribociclib
What this could lead to
If successful, this combination could offer a new treatment option for advanced HR+ breast cancer, potentially delaying disease progression.
What could go wrong
This is an early Phase 2 trial with only 150 participants, so results may not confirm effectiveness. Side effects from the drug combination are possible and not yet fully known.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beata Maria Ana
ACTIVE_NOT_RECRUITINGMadrid, Spain
-
H Quirónsalud Sagrado Corazón
ACTIVE_NOT_RECRUITINGSeville, Spain
-
HU Virgen de las Nieves
ACTIVE_NOT_RECRUITINGGranada, Spain
-
HUAV Valencia
RECRUITINGValencia, Spain
-
Hospital Clínic Barcelona
RECRUITINGBarcelona, Spain
-
Hospital Dexeus
RECRUITINGBarcelona, Spain
-
Hospital General Universitario Dr. Balmis
ACTIVE_NOT_RECRUITINGAlicante, Spain
-
Hospital Ramón y Cajal
ACTIVE_NOT_RECRUITINGMadrid, Spain
-
Hospital Regional Universitario de Málaga
ACTIVE_NOT_RECRUITINGMálaga, Spain
-
Hospital Universitario de Jerez de la Frontera
RECRUITINGJerez de la Frontera, Spain
-
Hospital Universitario de León
RECRUITINGLeón, Spain
-
Hospital Universitario y Politécnico de La Fe
ACTIVE_NOT_RECRUITINGValencia, Spain
-
IVO - Instituto Valenciano de Oncología
RECRUITINGValencia, Spain
-
Institut Català d'Oncologia Girona - ICO Girona
RECRUITINGGirona, Spain
-
Sant Joan de Reus
RECRUITINGReus, Spain
-
Städtisches Klinikum Dessau
ACTIVE_NOT_RECRUITINGDessau, Germany